Solventum (SOLV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SOLV broke through the 200-day moving average, which suggests a long-term bullish trend.The 200-day simple moving average is widely-used by traders and analysts, and helps establish market trends for stocks, commodities, indexes, and other financial instruments over the long term. The indicator moves higher or lower together with longer-term price moves, serving as a support o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-41968 SOLVENTUM CORPORATION (Exact name of registrant as specified in its charter) (State or other ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas in real-time, just join our community at The Biotech Forum by clicking HERE .Today, I am putting a medical solution and medical device provider Solventum Corporation (NYSE: SOLV ) for the first time since my initial article on this recent spinoff early l ...

Solventum (SOLV) reported first-quarter 2025 adjusted earnings per share (EPS) of $1.34, which beat the Zacks Consensus Estimate of $1.19 by 12.6%. The bottom line declined 35.6% year over year.GAAP EPS in the quarter was 78 cents, down 43.1% from the year-ago quarter’s level. (Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.)Revenue DetailsThe company reported revenues of $2.07 billion, up 2.6% reportedly from the prior-year recorded number. Organically, sales were up 4.3%. The met ...

For the quarter ended March 2025, Solventum (SOLV) reported revenue of $2.07 billion, up 2.7% over the same period last year. EPS came in at $1.34, compared to $2.08 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2 billion, representing a surprise of +3.37%. The company delivered an EPS surprise of +12.61%, with the consensus EPS estimate being $1.19.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expecta ...

Solventum (SOLV) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $2.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.61%. A quarter ago, it was expected that this health care company would post earnings of $1.31 per share when it actually produced earnings of $1.41, delivering a surprise of 7.63%.Over the last four quarters, the com ...

Solventum (SOLV) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance CommunicationsBryan Hanson - CEOWayde McMillan - Chief Financial OfficerPatrick Wood - Managing DirectorDavid Roman - Managing DirectorTravis Steed - Managing Director - Equity Research Conference Call Participants Rick Wise - AnalystJason Bednar - Senior Research AnalystNone - AnalystSteven Valiquette - MD & Senior Equity Research Analyst - Coveri ...

Solventum (SOLV) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon. My name is Amy, and I will be your conference call operator for today. I would like to welcome everyone to the Solventum First Quarter twenty twenty five Earnings Call. As a reminder, this call is being recorded and all lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Thank you. I would now like to turn the program over to your host ...

Q1 FY25 earnings presentation May 8, 2025 © Solventum 2025. All rights reserved. Forward-looking statements and use of document This presentation and other materials Solventum has filed or will file with the U.S. Securities & Exchange Commission ("SEC") (and oral communications that Solventum may make) contain or incorporate by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements ...

Exhibit 99.1 Organic sales growth in the quarter reflect positive performance from all segments, primarily driven by the MedSurg and HIS segments. GAAP and adjusted operating income margin declined due to lower gross margins, including the impact from 3M supply agreement mark-up, and an increase in operating expenses related to public company stand-up costs and growth investments. Represents non-GAAP financial measure; see the "Non-GAAP Financial Measures" section for applicable information. 1 1 • Reported ...